Product NDC: | 52682-023 |
Proprietary Name: | Carisoprodol and Aspirin |
Non Proprietary Name: | Carisoprodol and Aspirin |
Active Ingredient(s): | 325; 200 mg/1; mg/1 & nbsp; Carisoprodol and Aspirin |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 52682-023 |
Labeler Name: | Mirror Pharmaceuticals LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA040832 |
Marketing Category: | ANDA |
Start Marketing Date: | 20110609 |
Package NDC: | 52682-023-03 |
Package Description: | 500 TABLET in 1 BOTTLE, PLASTIC (52682-023-03) |
NDC Code | 52682-023-03 |
Proprietary Name | Carisoprodol and Aspirin |
Package Description | 500 TABLET in 1 BOTTLE, PLASTIC (52682-023-03) |
Product NDC | 52682-023 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Carisoprodol and Aspirin |
Dosage Form Name | TABLET |
Route Name | ORAL |
Start Marketing Date | 20110609 |
Marketing Category Name | ANDA |
Labeler Name | Mirror Pharmaceuticals LLC |
Substance Name | ASPIRIN; CARISOPRODOL |
Strength Number | 325; 200 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Centrally-mediated Muscle Relaxation [PE],Muscle Relaxant [EPC],Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |